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Mitochondrial therapy for doxorubicin
cardiomyopathy: nuclear factor-jB to the rescue?
Kirsten Theresa Nijholt , Berend Daan Westenbrink , and Rudolf Allert de Boer *
Department of Cardiology, University Medical Center Groningen, University of Groningen, AB 31, PO Box 30.001, Groningen 9700 RB, The Netherlands
Online publish-ahead-of-print 23 December 2019
This editorial refers to ‘Impaired NF-jB signalling underlies
cyclophilin D-mediated mitochondrial permeability transition
pore opening in doxorubicin cardiomyopathy’, by R. Dhingra
et al., pp. 1161–1174.
Anthracyclines are the most commonly used and most effective chemo-
therapeutic agents. Doxorubicin (Dox) was the first anthracycline intro-
duced into the clinical arena in the 1970s and its use resulted in dramatic
improvements in survival and quality of life for many cancer patients.1
Unfortunately, this success came with untoward side-effects in the form
of significant cardiotoxicity. Cardiotoxic side effects occur in up to 30%
of patients treated with anthracyclines, ranging from mild and reversible
contractile dysfunction to severe and progressive-dilated cardiomyopa-
thy and chronic heart failure.1 Cardiotoxic side effects are the most com-
mon reasons to discontinue anthracycline-based chemotherapy, thereby
limiting the individual chances of survival.1 Therapeutic strategies to pre-
vent cardiotoxicity in patients receiving anthracycline-based chemother-
apy are urgently needed.
Over the years, intense efforts have been directed at unravelling the
mechanisms responsible for Dox-induced cardiotoxicity. In the mito-
chondria, generation of excessive reactive oxygen species, accumulation
of iron-Dox complexes and enhanced calcium influx lead to cardiomyo-
cyte dysfunction and ultimately cell death.1,2 The heart requires tremen-
dous amounts of ATP to maintain its mechanical work and is, therefore,
highly dependent on properly functioning mitochondria.1 In addition to
their role in cardiac bioenergetics, mitochondria are also essential for
cardiac calcium handling, cardiac signal transduction, and the initiation
and execution of cell death. Recently, evidence is accumulating that
impediments in mitochondrial iron and calcium handling lead to cell
death and are central to the development of Dox-induced cardiotoxic-
ity.1,2 The mechanisms underlying these impediments are poorly de-
scribed but could offer therapeutic targets to prevent Dox-induced
cardiotoxicity.
The article by Dhingra et al. is part of this continued effort by their and
other research groups to unravel mitochondrial pathways that control
cell death in cardiomyocytes. While NF-jB is often considered to be a
villain in cardiac physiology, the authors have previously demonstrated
that activation of NF-jB can suppress cardiomyocyte necrosis during
myocardial ischaemia/reperfusion injury. Cardio-protection offered by
NF-jB is at least partially mediated by NF-jB-mediated transcriptional
repression of Bcl-2/adenovirus E1B 19Kda protein-interacting protein 3
(Bnip3).3 Bnip3 is a member of the Bcl-2 protein family which control
the permeability of the outer mitochondrial membrane. Depending on
the cellular context and post-translational modifications to Bnip3, ex-
pression of Bnip3 can promote cell death or foster cell survival. In the
context of Dox-induced cardiomyopathy, transcriptional activation of
Bnip3 has been implicated in the promotion of mitochondrial permeabil-
ity transition pore (mPTP) opening leading to cardiomyocyte necrosis.4
The mechanisms responsible for Dox-induced Bnip3 transcription are
only partially understood, and the mode by which Bnip3 provokes mPTP
opening is unknown. Based on their previous work, the authors hypothe-
sized that inhibition of NF-jB and subsequent de-repression of Bnip3
could be responsible for Dox-induced mPTP formation and cell death.
This hypothesis was tested in a series of experiments in Dox-treated
mice and neonatal rat ventricular cardiomyocytes (NRVCs).5
First, it was confirmed that Dox reduces NF-jB activity in cardiomyo-
cytes, associated with increased Bnip3 expression, calcium-induced mi-
tochondrial swelling and mPTP formation. The importance of mPTP
formation in Dox-induced cell death was also established through knock
down or inhibition of Cyclophilin D (CyP-D), a well-established compo-
nent of the mPTP. Next, the general association between the suppres-
sion NF-jB and mPTP formation was established through gain and loss
of function experiments with NF-jB and CyP-D. Furthermore, overex-
pression of IKKb was sufficient to reverse mPTP formation and cell
death, indicating that suppression of NF-jB is required for Dox-induced
cardiac injury. The final and perhaps most significant discovery was that
both Bnip3-mediated mPTP formation and Bnip3-mediated cell death
were found to be contingent upon the association between Bnip3 and
CyP-D. Hence, this study integrates a number of previous independent
observations to establish a novel signalling pathway in which suppression
of NF-jB sets the stage for Bnip3-mediated mPTP formation and
cell death. The study also provides reassuring proof that we may 1 day
be able to prevent or reverse anthracycline-induced cardiomyopathy.
Finally, the study leaves us with promising nodal points for intervention
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including stimulation of NF-jB activity, suppression of Bnip3
transcription or prevention or disruption of the Bnip3-Cyp-D protein
complex.3–5
The study by Dhingra et al. provides new insights that are welcomed
in the cardio-oncology field. The finding that Dox-activated signalling
pathways regulate mPTP formation is in accordance with other studies
and suggests that other regulators of mPTP formation could prevent
anthracycline-associated cardiomyopathy as well.6,7 The contribution of
mPTP formation to Dox-mediated cardiac injury is not well described
and mostly involves experiments in cultured cardiomyocytes or isolated
mitochondria.8 The temporal patterns of mPTP-mediated cell death
after Dox administration are, therefore, unknown but are probably
short-lived. This does not necessarily represent a therapeutic limitation,
as sustained activation of NF-jB could promote tumour growth and
cause cardiac inflammation.9
Another therapeutic avenue to overcome Dox-induced mitochon-
drial injury could lie in targeting mitochondrial dynamics. For instance,
Abdullah et al.10 have shown that dysregulated mitochondrial dynamics
and impaired mitochondrial respiration play a prominent role in
Dox-induced cardiotoxicity. Inhibition of mitophagy promotes apoptosis
and mitochondrial dysfunction after Dox treatment, whereas stimulation
of mitophagy may have protective effects.11 Stimulating mitochondrial
biogenesis also appears to be protective in Dox-induced cardiotoxicity.
As up-regulation of PGC1-alpha and its downstream factors including
tFAM and NRF-1/2 reduce Dox-induced cardiotoxicity.12,13 Of note,
this protection was accompanied by the inhibition of NF-jB, reinforcing
the notion that the protection offered by NF-jB may be temporary
in vivo.13 Interestingly, exercise training is known to stimulate mitochon-
drial biogenesis and also stimulates mitophagy in rats treated with
Dox.8,14,15 Therefore, exercise may also offer protection against Dox-
induced cardiotoxicity by enhancing mitochondrial quality control.
Taken together, the study by Dhingra et al. reveals a unique and
novel signalling pathway responsible for Dox-induced mPTP forma-
tion and cell death, which offers several nodal points for intervention.
The translational potential obviously is somewhat limited because the
study predominantly focused on the use of NRVCs. Future studies
are, therefore, required to establish the true relevance in vivo.
Furthermore, it is likely that Dox-induced mPTP formation is short-
lived. Interventions focused on improving mitochondrial quality con-
trol could, therefore, offer the second line of defense after Dox
administration. Mitochondrial targeted therapy against Dox-induced
cardiomyopathy may, therefore, require a staged approach (summa-
rized in Figure 1). Therapies that stimulate NF-jB, inhibit Bnip3, or
disrupt the association with Cyp-D, could offer protection early after
Dox-infusion. In the later stages, therapies directed at restoring mito-
chondrial fitness may be more forthcoming. This may include meas-
ures as simple as implementing an exercise regimen. Concludingly,
these findings provide the evidence to develop novel therapeutic
interventions to prevent or reverse Dox-induced cardiotoxicity.
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Figure 1 (A) Staged approach of potential mitochondrial targets to
attenuate Dox-induced cardiotoxicity, ranging from acute to more
chronic stages after Dox administration. (B) Underlying mitochondrial
and cell death mechanisms leading to Dox-induced cardiotoxicity.
Bnip3, Bcl-2/19 kDa interacting protein 3; mPTP, mitochondrial perme-
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